Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7369 - 7376 of 12142 results
Data Breaches Will Cost Yahoo and Verizon Long After Sale
February 27, 2017| Blog| Viewpoint
Federal Circuit Clarifies Scope of Covered Business Method Review
February 27, 2017| Blog| Viewpoint
Update: DOL Regulation for Employers Who Use Direct Deposit and Payroll Debit Cards Invalidated
February 27, 2017| Alert| Viewpoint
Does the Show Stop For Appeal After a Court Compels Arbitration? The Federal Circuit Courts Are Split
February 24, 2017| Blog| Viewpoint
Medicaid Financing Reform: Per Capita Caps vs. Block Grants
February 24, 2017| Blog| Viewpoint
What will happen to Ole Miss, Hugh Freeze in NCAA investigation? Experts weigh in
February 24, 2017| News
Sale-Leasebacks: Cash Out but Keep Control
February 23, 2017| Blog| Viewpoint
Massachusetts Health Care Industry Facing Policy Changes
February 23, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”